Advaxis up on advancement of prostate cancer candidate into clinic

Nano cap Advaxis (ADXS +22.4%) jumps on a more than double normal volume in reaction to the FDA’s sign-off on its IND for a Phase 1 study evaluating ADXS-504 in prostate cancer patients.

ADXS-504 is the company’s ADXS-HOT candidate for the indication, an off-the-shelf neoantigen that targets hotspot mutations in tumor driver genes.

https://seekingalpha.com/news/3530143-advaxis-up-22-on-advancement-of-prostate-cancer-candidate-clinic